
    
      A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With
      Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First Line Therapy or
      When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
    
  